Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) Vice President Tami Tillotson Martin sold 5,000 shares of Supernus Pharmaceuticals in a trade that took place on Thursday, August 4. The stock was sold at an average price of $32.98, for a total transaction of $164,900.00. Following the completion of the sale, the vice president now directly owns 87,220 shares of the company, valued at $2,876,515.60. The transaction was disclosed in a legal filing with the SEC, accessible via the SEC’s website.
Supernus Pharmaceuticals stock down 2.0%
Shares of SUPN opened at $32.16 on Friday. The company has a market capitalization of $1.72 billion, a PE ratio of 31.84 and a beta of 1.04. The company’s fifty-day moving average is $29.18 and its two-hundred-day moving average is $29.82. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $34.50. The company has a quick ratio of 1.69, a current ratio of 2.00 and a leverage ratio of 0.48.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last reported quarterly results on Thursday, August 4. The specialty pharmaceutical company reported earnings per share of $0.14 for the quarter, missing consensus analyst estimates of $0.29 per ($0.15). The company posted revenue of $170.10 million in the quarter, compared to analyst estimates of $164.23 million. Supernus Pharmaceuticals had a net margin of 9.12% and a return on equity of 7.03%. The company’s revenue for the quarter increased 20.4% compared to the same quarter last year. In the same quarter last year, the company achieved EPS of $0.43. Analysts expect Supernus Pharmaceuticals, Inc. to post 1.64 earnings per share for the current year.
Analyst upgrades and downgrades
SUPN has been the subject of several recent analyst reports. StockNews.com upgraded Supernus Pharmaceuticals shares from a “hold” rating to a “buy” rating in a Monday, April 18 research note. TheStreet reduced shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a Monday, April 18 research note.
Hedge funds weigh on Supernus Pharmaceuticals
A number of hedge funds have recently changed their positions in SUPN. Woodline Partners LP acquired a new position in Supernus Pharmaceuticals stock in Q1 worth $15,689,000. Stephens Investment Management Group LLC increased its holdings of Supernus Pharmaceuticals shares by 27.2% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,577,980 shares of the specialty pharmaceutical company valued at $46,014,000 after acquiring 337,902 additional shares last quarter. Lisanti Capital Growth LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter at a value of $8,878,000. Goldman Sachs Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 108.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company valued at $17,779,000 after acquiring an additional 285,737 shares last quarter. Finally, GW&K Investment Management LLC increased its stake in Supernus Pharmaceuticals shares by 13.0% during the 4th quarter. GW&K Investment Management LLC now owns 1,836,466 shares of the specialty pharmaceutical company valued at $53,551,000 after acquiring an additional 210,976 shares last quarter.
About Supernus Pharmaceuticals
(Get a rating)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended-release topiramate indicated for the treatment of epilepsy, as well as for the prophylaxis of migraines; and Oxtellar XR, an extended-release oxcarbazepine for the monotherapy treatment of partial-onset seizures in adults and children aged 6 to 17 years.
Get news and reviews for Supernus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.